Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06521554 · ClinicalTrials.gov registry record · Phase 1
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
A Phase 1 study of Metastatic Solid Tumor and Locally Advanced Solid Tumor, sponsored by Nuvalent.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06521554 is a Phase 1 study of Metastatic Solid Tumor and Locally Advanced Solid Tumor that is actively recruiting participants, run by Nuvalent. The registered enrollment target is 200 participants, roughly in line with the 188-participant average among 52 other Metastatic Solid Tumor trials with a reported enrollment target. The trial reports 20 study locations across 16 states.
The verdict
NCT06521554, a Phase 1 study of Metastatic Solid Tumor and Locally Advanced Solid Tumor, is actively recruiting participants, sponsored by Nuvalent.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in participants with advanced or metastatic human epidermal growth factor receptor 2 (HER2) -altered non-small lung cancer (NSCLC). Phase 1a dose escalation is designed to assess the safety and tolerability of NVL-330 and to select the candidate RP2D(s) and, if applicable, the MTD. Phase 1b expansion is designed to further evaluate the overall safety and tolerability of the candidate RP2D(s) of NVL-330 and to determine the RP2D of NVL-330 in participants with advanced or metastatic HER2 mutant NSCLC.
Conditions Studied
Interventions
- DRUG NVL-330
Study Locations (20)
California
- City of Hope - Lennar - Irvine
- University of California, Davis Comprehensive Cancer Center - Sacramento
- Stanford Cancer Institute - Stanford
District of Columbia
- Georgetown University Medical Center - Washington D.C.
- Sibley Memorial Hospital - Washington D.C.
New South Wales
- Chris O'Brien Lifehouse - Camperdown
- North Shore Health Hub - Saint Leonards
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Florida
- Sylvester Comprehensive Cancer Center - Miami
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview Medical Center - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Henry Ford Cancer Center - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-07-18 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06521554
The ClinicalTrials.gov registry entry for NCT06521554 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 188-participant average among 52 other Metastatic Solid Tumor trials with a reported enrollment target. The listed sponsor is Nuvalent, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which NVL-330 is the first listed.
NCT06521554 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, District of Columbia, New South Wales.
Frequently Asked Questions
What is clinical trial NCT06521554 about?
NCT06521554 is a clinical study titled "A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)". Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in participants with advanced or metastatic human epidermal growth factor receptor 2 (HER2) -altered non-sma...
What is the current status of trial NCT06521554?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2024-07-18. Estimated completion is 2027-02.
What conditions does trial NCT06521554 study?
This clinical trial studies the following conditions: Metastatic Solid Tumor, Locally Advanced Solid Tumor.
What interventions are being tested in trial NCT06521554?
The interventions under investigation include: NVL-330 (DRUG).
Who is sponsoring clinical trial NCT06521554?
This trial is sponsored by Nuvalent, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06521554 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
RECRUITING · Phase 1
-
A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.